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Objectives. The present study describes an isolated defect of the
coronary vasodilation in response to adenosine in five patients
examined for clinically suspected coronary microangiopathy.
Background. Coronary microangiopathies can be defined func-
tionally as dysregulation of the microcirculatory vasomotion.
Methods. The five patients were compared with 24 control
subjects. Coronary flow velocity was measured with an intracoro-
nary Doppler guide wire (0.018 in. [0.046 cm], 12 MHz) at rest
and during intracoronary administration of adenosine (80 mg/min
and 160 mg/min over 3 min each), papaverine (10-mg bolus) and
acetylcholine (30 mg/min over 5 min). Diameters of the epicardial
coronary arteries were measured by quantitative coronary angiog-
raphy.
Results. All subjects (patients and control) exhibited angio-
graphically normal epicardial coronary arteries and normal and
comparable endothelium-independent and -dependent vasomo-
tion, as assessed with papaverine (mean [6 SD] relative coronary
flow reserve 2.62 6 0.66 vs. 2.97 6 0.88, p 5 0.32) and acetylcho-
line (volumetric coronary flow reserve 2.61 6 0.27 vs. 2.91 6 0.67,
p 5 0.58), respectively. Affected patients were identified by an
isolated complete defect of the adenosine-mediated vasodilation
compared with control subjects (relative coronary flow reserve in
response to 80 mg/min of adenosine 1.08 6 0.17 vs. 2.45 6 0.74
[p < 0.001] and 160 mg/min of adenosine 1.03 6 0.15 vs. 2.89 6
0.65 [p < 0.001]).
Conclusions. These findings are consistent with functional
evidence for a new entity of a coronary microangiopathy affecting
a subtype of the endothelium-independent vasomotion.
(J Am Coll Cardiol 1997;30:103–7)
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Coronary microangiopathies have to be differentiated clinically
from classic ischemic heart disease caused by atherosclerosis of
the epicardial coronary arteries. Affected patients usually
present with angina or angina-like chest pain and a normal
coronary angiogram of the epicardial vessels, referred to as
syndrome X (1), or belong to a risk group defined by an
underlying disease involving the microvasculature (e.g., accel-
erated transplant vasculopathy, vasculitic syndromes or meta-
bolic abnormalities) (2,3). In contrast to classic ischemic heart
disease, which is diagnosed by morphologic demonstration of
stenoses on the coronary angiogram, coronary microangiopa-
thies are usually detected by functional changes in coronary
vasomotor response. Because coronary vascular resistance is
primarily regulated by coronary arteries ,400 mm in diameter
(4), microcirculatory abnormalities result in an impairment of
the coronary vasodilation. Recently, impaired endothelium-
dependent vasodilation in response to acetylcholine has been
suggested as one form of microangiopathic dysregulation (5).
However, it can be speculated that the entity of coronary
microangiopathies is composed of a variety of different abnor-
malities of endothelial cells or vascular smooth muscle cells
presenting as endothelium-dependent as well as endothelium-
independent vasomotor dysregulations.
To improve characterization of the endothelium-independent
vasomotion, we evaluated patients presenting with suspected
coronary microangiopathy, but without evidence of endothelium-
independent vasomotor dysfunction in response to papaverine or
endothelium-dependent vasomotor dysfunction in response to
acetylcholine with adenosine, an alternative and well established
physiologic endothelium-independent vasodilator.
Methods
Study group. Fifty consecutive, normotensive and nondia-
betic patients (mean age 49 6 14 years) were routinely
investigated because of clinically suspected coronary microan-
giopathy. Thirty-three patients presented with a history of
unexplained angina-like chest pain with a normal coronary
angiogram, and 17 were evaluated as heart transplant recipi-
ents 39 6 32 months after transplantation, representing a risk
group with an especially high incidence of transplant vascu-
lopathy, an entity with accelerated coronary atherosclerosis
and potential immune-mediated microvascular injury (2,6,7).
All 50 patients had angiographically normal coronary arter-
ies and echocardiographically normal fractional shortening
($30%) and diastolic left ventricular wall thickness. After
exclusion of nine patients with angiographic evidence of
vasospastic angina by coronary vasoconstriction to acetyl-
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choline and 12 patients with evidence of microvascular
angina by an impaired vasomotor response to papaverine as
the endothelium-independent and to acetylcholine as the
endothelium-dependent vasoactive agent, 29 patients were
enrolled in the present study. Of these 29 patients without
evidence of any previously described morphologic or func-
tional abnormality of the coronary circulation, we identified
five patients with a complete defect of the adenosine-mediated
microcirculatory vasodilation.
Normal left ventricular function was demonstrated in each
patient by an ejection fraction $60% obtained by ventriculog-
raphy. No patient was medicated with methylxanthine-related
drugs. All patients were studied after written, informed con-
sent was obtained, and all studies were approved by the Ethics
Committee of the Ludwig-Maximilians-University of Munich.
Measurement of coronary flow velocity. All medications as
well as all caffeine-containing beverages were withheld for at
least 12 h before the examination. Patients were investigated in
a fasting state. Contrast ventriculography and coronary angiog-
raphy of the epicardial vessels were performed by a right
femoral approach. After intravenous administration of 2,000 U
of heparin, a 6F Judkins catheter was positioned at the left
coronary ostium and a 0.018-in. (0.046-cm), 12-MHz Doppler
wire (Cardiometrics, Inc.) was advanced into the proximal left
anterior descending coronary artery (n 5 25) or the proximal
circumflex artery (n 5 4). The Doppler wire position was
adjusted to obtain an adequate and stable signal of the
coronary flow velocity waveform. First, adenosine (Adrekar,
Sanofi-Winthrop, Germany) was given as a continuous intra-
coronary infusion at doses of 80 mg/min and 160 mg/min over
3 min each. Second, 10 mg of papaverine (Paveron, Linden,
Germany) was administered as an intracoronary bolus injec-
tion. Third, acetylcholine (Acetylcholin Disperga, Disperga,
Austria) was given as an intracoronary infusion at a dose of
30 mg/min over 5 min. Between each agent a complete return
to baseline values was presupposed. Average peak velocity,
mean arterial pressure and heart rate were monitored contin-
uously. Measurements were taken at rest and during maximal
hyperemia for each agent and dose. Coronary angiography of
the left coronary artery was performed in biplane views at the
end of each infusion or injection.
Quantitative coronary angiography. Angiograms were re-
corded on 35-mm cine film (50 frames/s). Each coronary
angiogram was evaluated qualitatively by two independent
cardiologists to rule out significant atherosclerotic lesions of
the epicardial coronary arteries. Quantitative coronary angiog-
raphy was performed using a validated videodensitometric
analysis system (Qansad 2.3., Arri, Munich, Germany). End-
diastolic frames of an appropriate view that allowed the best
visualization of the study artery were selected. For the segment
of interest, we measured the vessel lumen at a distance of 5 mm
from the Doppler wire tip, where the sample volume of the
Doppler ultrasound is located. The average value of three
measurements of the segment of interest was used for analysis.
Calculations and data analysis. The relative coronary flow
reserve (rCFR) for adenosine and papaverine was estimated as
the ratio of the maximal average peak velocity during pharma-
cologic hyperemia to the average peak velocity at rest, as these
vasoactive agents are reported to exhibit no direct vasodilating
effects on the epicardial conductance vessels (4). In contrast,
acetylcholine may induce different effects on the epicardial
conductance arteries and the microcirculatory resistance vessels
(8). To incorporate measures of epicardial and microcirculatory
vasoactivity, the volumetric coronary flow reserve (vCFR) for
acetylcholine was estimated from the ratio of the products of the
coronary flow velocity and the cross-sectional area of the corre-
sponding arterial segment (calculated as p 3 [diameter/2]2 with
the averaged diameter derived from measurements by quanti-
tative coronary angiography) during pharmacologic hyperemia
and at rest (9). Using the Doppler technique, coronary blood
flow reserve $2.0 was considered normal (10).
Statistical analysis. Data are expressed as mean value 6
SD. Because the underlying distribution of the data was
unknown, nonparametric statistics were used. To incorporate
two independent levels of factors, the data analysis was per-
formed with the nonparametric Friedman two-way analysis of
variance by ranks (11). At p , 0.01, post hoc comparisons
between pairs of means were performed by using the Wilcoxon
rank-sum test with downward adjustment of the level to
compensate for multiple comparisons. Otherwise, the Mann-
Whitney U test and Fisher exact test were used to compare two
groups of continuous and nominal variables, respectively. A
two-tailed p value , 0.01 was considered significant. Statistical
analysis was performed by using the software program “Stat-
View,” version 4.1 (Abacus Concepts).
Results
Clinical characteristics (Table 1). By post hoc comparison
between the patients with an adenosine defect and the remain-
ing control subjects, age, body mass index or baseline systemic
hemodynamic variables (mean arterial pressure and heart rate)
did not differ between the two groups. All three nontransplant
patients with an adenosine defect presented with symptoms of
angina pectoris and electrocardiographic ST segment abnor-
malities during exercise.
Measurements (Table 2). In five subjects, intracoronary
infusion of adenosine (80 and 160 mg/min) did not alter
coronary blood flow, whereas papaverine and acetylcholine
induced a comparable and significant increase in average peak
velocity (patients with an adenosine defect). In the remaining
subjects, adenosine (80 and 160 mg/min) as well as papaverine
and acetylcholine induced a comparable highly significant
increase in average peak velocity (control subjects). The
baseline average peak velocity of coronary blood flow and the
diameter of the study artery were also similar in the patients
Abbreviations and Acronyms
rCFR 5 relative coronary flow reserve
vCFR 5 volumetric coronary flow reserve
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and control subjects. Although heart rate did not change
significantly throughout the whole investigation, intracoronary
administration of papaverine induced a slight but significant
drop in mean arterial pressure in both groups (without signif-
icant difference between both groups). Acetylcholine did not
induce significant changes in the coronary artery diameter of
the study artery in either group.
Coronary flow reserve (Table 3, Fig. 1). All subjects (pa-
tients with an adenosine defect and control subjects) exhibited
a comparable rCFR in response to papaverine and vCFR in
response to acetylcholine within the normal range using the
Doppler technique. In the patients with an adenosine defect,
the absent effect of intracoronary infusion of adenosine on
average peak velocity is reflected by a significantly decreased
rCFR in response to 80 and 160 mg/min of adenosine. In
contrast, the remaining control subjects showed a normal
rCFR in response to adenosine.
To retest the reproducibility of the measurements, one
patient (Patient 5 in Tables 1 and 3) was reevaluated 12 months
after the initial testing, demonstrating persistence of the defective
adenosine-mediated vasodilation (rCFR 1.10 and 1.20 in re-
sponse to 80 and 160 mg/min of adenosine, respectively) with still
normal endothelium-dependent vasodilation to acetylcholine
(vCFR 2.00).
Discussion
The present study describes an isolated defect of the
coronary vasodilation to adenosine in five patients with other-
wise intact endothelium-dependent and -independent function
of the microvasculature and angiographically normal epicar-
dial coronary arteries.
Causes of microangiopathic dysfunction of the coronary
circulation can be subdivided into 1) structural disease pro-
cesses resulting in histologic abnormalities of the small vessels,
and 2) functional dysregulations without morphologic alter-
ations. Involvement of the small coronary arteries by a number
of systemic (diabetes mellitus, atherosclerosis, hypertension)
and organ-specific (dilated cardiomyopathy, transplant arterio-
sclerosis) disease processes induces impairment of endothelium-
dependent vasodilation of epicardial (12–14) and microcircu-
latory vessels (15,16), correlating with structural changes as
intimal and medial hyperplasia, necrosis, dissection or throm-
bosis (3). In contrast, Egashira et al. (5) described attenuated
endothelium-dependent vasodilation of the resistance coro-
Table 1. Clinical Characteristics of Five Patients With the Adenosine Defect and Twenty-Four Control
Subjects
Age (yr)/Gender Diagnosis
BMI
(kg/m)
MAP
(mm Hg)
HR
(beats/min)
Study
Artery
Patients
Pt 1 66/M Syndrome X 50.0 121 58 LAD
Pt 2 50/F Syndrome X 38.5 130 78 LAD
Pt 3 52/M 32 mo after HTx 42.1 106 81 LAD
Pt 4 39/F Syndrome X 45.7 109 111 LCx
Pt 5 59/M 24 mo after HTx 51.4 158 81 LCx
Mean 53.2 45.5 124.8 81.8
6SD 610.1 65.4 620.9 618.9
Control
Mean 46.1 43.2 116.2 81.5 LAD (n 5 22),
6SD 616.5 65.2 617.6 613.9 LCx (n 5 2)
p value 0.53 0.36 0.62 0.86
BMI 5 body mass index; Control 5 control subjects (20 men, 4 women); F 5 female; HR 5 heart rate; HTx 5 heart
transplantation; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; M 5 male;
MAP 5 mean arterial pressure; Pt 5 patient.
Table 2. Blood Pressure, Heart Rate, Average Peak Velocity and Coronary Artery Diameter in Five Patients With the Adenosine Defect and
Control Subjects at Rest and During Pharmacologic Stimulation
Patients With Adenosine Defect Control Subjects
MAP
(mm Hg)
HR
(min21)
APV
(cm/s)
CA
Diam
(mm)
MAP
(mm Hg)
HR
(min21)
APV
(cm/s)
CA
Diam
(mm)
Baseline 124.8 6 20.9 81.8 6 18.9 24.6 6 9.0 3.97 6 0.64 116.2 6 17.6 81.5 6 13.9 29.5 6 11.3 3.74 6 1.18
Adenosine (80 mg/min IC) 123.2 6 19.0 88.4 6 21.5 27.3 6 12.4 113.0 6 16.6 80.4 6 14.2 69.1 6 24.3*†
Adenosine (160 mg/min IC) 119.0 6 19.1 92.2 6 19.6 25.3 6 10.8 112.8 6 14.5 79.9 6 13.5 80.6 6 13.5*‡
Papaverine (10 mg IC) 105.0 6 11.7 83.2 6 8.5 63.5 6 24.4* 98.4 6 11.3 85.0 6 13.3 85.6 6 18.6*
Acetylcholine (30 mg/min IC) 125.2 6 15.6 88.4 6 19.9 52.2 6 17.6* 4.38 6 0.95 112.5 6 14.9 79.2 6 13.7 77.3 6 26.3* 3.71 6 1.19
*p , 0.001, acetylcholine, papaverine or adenosine versus baseline. †p , 0.01, ‡p , 0.001, patients versus control subjects. Data are presented as mean value 6
SD. APV 5 average peak velocity; CA Diam 5 coronary artery diameter; IC 5 intracoronary; other abbreviations as in Table 1.
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nary arteries to acetylcholine, but normal endothelium-
independent vasodilation in patients with microvascular angina
as a functional defect of the coronary microcirculation. How-
ever, an isolated defect of the endothelium-independent vaso-
dilation has not been described so far.
Functional characterization of microangiopathies. The
potential to functionally characterize the coronary microcircu-
lation by assessment of changes in coronary blood flow is based
on the fact that myocardial perfusion is regulated by coronary
vascular resistance. Different neuronal and humoral factors are
capable of modulating this regulation (4). These modulating
mechanisms can be subdivided into endothelium-dependent
and endothelium-independent effects.
With intracoronary administration of endothelium-dependent
and -independent vasodilators, the catheter-based intravascu-
lar Doppler technique allows isolated assessment of these
different functional pathways. The classic agent to characterize
endothelial function is acetylcholine. Besides its vasodilating
properties in the smaller resistance vessels, acetylcholine also
exhibits potential direct vasoconstriction effects on the epicar-
dial arteries (8). Therefore, acetylcholine-mediated effects are
assessed as volumetric flow reserve incorporating changes of
the epicardial lumen. As epicardial vasoconstriction is a well
described phenomenon in atherosclerotic coronary arteries
(17), all patients with acetylcholine-induced epicardial vaso-
constriction .10% were excluded from this study. Endothelium-
independent vasodilation is routinely assessed by papaverine
(13) or adenosine (14). In the absence of effects on epicardial
vessels (18–20), the net effects of these agents can be assessed as
rCFR only incorporating microcirculatory effects.
Potential cellular background. Endogenous adenosine has
been recognized as an important paracrine coronary vasodila-
tor. In contrast to the adenosine1 receptor-mediated modula-
tion of chronotropy, dromotropy and inotropy, the vasodilating
Table 3. Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow
Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty-Four Control Subjects
Relative Coronary Flow Reserve
vCFR
Acetylcholine
(30 mg/min IC)
Adenosine
(80 mg/min IC)
Adenosine
(160 mg/min IC)
Papaverine
(10 mg IC)
Patients
Pt 1 1.23 1.14 2.01 2.37
Pt 2 1.29 1.02 3.11 2.93
Pt 3 0.94 1.12 2.40 2.81
Pt 4 0.91 0.77 3.51 2.63
Pt 5 1.04 1.11 2.07 2.32
Mean 1.08 1.03 2.62 2.61
6SD 60.17 60.15 60.66 60.27
Control
Mean 2.45 2.89 2.97 2.91
6SD 60.74 60.65 60.88 60.67
p value * * 0.32 0.58
*p , 0.001, patients versus control subjects. vCFR 5 volumetric coronary flow reserve; other abbreviations as in
Tables 1 and 2.
Figure 1. Coronary flow reserve in
patients with a defect of the
adenosine-mediated vasodilation
and in control subjects in response
to adenosine (80 and 160 mg/min
intracoronary [i.c.] over 3 min
each), papaverine (10-mg intra-
coronary bolus) and acetylcholine
(30 mg/min intracoronary over
5 min). Coronary flow reserve $2.0
was considered normal. Data are
expressed as mean value 6 SD.
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properties are mainly mediated by an adenosine2 receptor
subtype on vascular smooth muscle cells linked to adenylate
cyclase through a stimulatory G protein (21). Because the
direct vasodilating properties of papaverine are related to its
ability to inhibit phosphodiesterase, thereby increasing intra-
cellular cyclic adenosine monophosphate, the isolated defect
of the adenosine-mediated vasodilation suggests a defect at the
level of the adenosine2 receptor, the relevant Gs protein or the
receptor/effector coupling with the myogenic adenylate cy-
clase. Alternatively, one could speculate that a pathophysi-
ologically altered adenosine2/adenosine1 receptor ratio in vas-
cular myocytes would diminish the vasodilating net effect to
exogenous adenosine. Indeed, the coexistence of a certain
adenosine1 receptor subtype in vascular smooth muscle cells
was recently suggested, which should be linked to adenylate
cyclase in an inhibitory manner (22). The presence of the
adenosine defect not only in normally innervated hearts but
also in transplanted hearts underlines the paracrine nature of
the described defect and provides a strong argument against
the involvement of components of the receptor/effector cas-
cade of autonomic neurotransmitters. Interestingly, patients
with defective adenosine-mediated vasodilation also exhibit
only slightly diminished coronary flow reserve to acetylcholine
and papaverine. One might speculate about a minimal reflexive
paracrine liberation of endogenous adenosine in response to
the papaverine- and acetylcholine-mediated hyperemia, which
would also be ineffective in affected patients.
To further elucidate the cellular background of the de-
scribed entity, further clinical studies comparing the dose-
response characteristics of adenosine1 and adenosine2 agonists
and antagonists, as well as in vitro studies evaluating the expres-
sion and distribution of the components of the adenosine recep-
tor/effector system in affected coronary arteries, are needed.
Clinical implications. Endogenous adenosine plays an im-
portant role as a paracrine nucleoside with marked cardiopro-
tective properties. Released in response to hypoxemia or
ischemia, adenosine can regulate the oxygen supply/demand
ratio by increasing oxygen supply through adenosine2 receptor-
mediated coronary vasodilation and by reducing oxygen de-
mand through an adenosine1 receptor-mediated decrease of
myocardial contractility and depression of chronotropy and
dromotropy (23). In the ischemic myocardium, adenosine has
been implicated in myocardial preconditioning (24) with an
infarct size-limiting potential. During postischemic reperfu-
sion, adenosine has been reported to attenuate myocardial
stunning (25). Therefore, the defect of the adenosine-
mediated coronary vasodilation physiologically represents a
partial loss of the endogenous cardioprotective properties of
the heart, exposing patients to an increased risk of myocardial
damage during hypoxemia or ischemia. The significant contri-
bution of the adenosine effect to the coronary vasodilation was
recently demonstrated by an exacerbation of myocardial isch-
emia during exercise after inactivation of adenosine or aden-
osine receptor antagonism (26).
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